Pre-clinical and clinical studies demonstrate key promise for ghrelin as a heart failure biomarker and an inotropic agent, given its prior demonstration of increased cardiac contractility and inhibition of cardiac myocyte apoptosis during cardiovascular remodeling. The gene discussed is GHRL; the disease is heart failure.